2020年美国临床肿瘤学会亮点：慢性淋巴细胞白血病治疗的最新进展
Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia.
作者信息
Dolan S, Christofides A, Doucette S, Shafey M
机构信息
Dalhousie University, St. John, NB.
impact Medicom Inc., Toronto, ON.
出版信息
Curr Oncol. 2020 Aug;27(4):e420-e432. doi: 10.3747/co.27.7009. Epub 2020 Aug 1.
Abstract
Because of the global coronavirus pandemic, the 2020 annual scientific meeting of the American Society of Clinical Oncology took place virtually, 29-30 May. At the meeting, results from key studies about the treatment of chronic lymphocytic leukemia (cll) were disseminated. Studies examined the efficacy and safety of ibrutinib, acalabrutinib, zanubrutinib, and venetoclax as monotherapy or in combination with novel agents for patients with treatment-naïve and relapsed or refractory cll. Our meeting report describes the foregoing studies and presents interviews with investigators and commentaries by Canadian hematologists about potential effects on Canadian practice.
摘要
由于全球冠状病毒大流行，美国临床肿瘤学会2020年年度科学会议于5月29日至30日以线上形式举行。会议上公布了关于慢性淋巴细胞白血病（CLL）治疗的关键研究结果。这些研究考察了伊布替尼、阿卡替尼、泽布替尼和维奈克拉作为单药治疗或与新型药物联合用于初治、复发或难治性CLL患者的疗效和安全性。我们的会议报告描述了上述研究，并展示了对研究人员的采访以及加拿大血液学家对其对加拿大临床实践潜在影响的评论。
相似文献
1
Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia.2020年美国临床肿瘤学会亮点：慢性淋巴细胞白血病治疗的最新进展
Curr Oncol. 2020 Aug;27(4):e420-e432. doi: 10.3747/co.27.7009. Epub 2020 Aug 1.
2
Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia.美国血液学会 2019 年年会更新：治疗初治慢性淋巴细胞白血病的具有改变实践意义的研究。
Curr Oncol. 2020 Apr;27(2):e231-e245. doi: 10.3747/co.27.6291. Epub 2020 May 1.
3
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.评估阿卡替尼在治疗慢性淋巴细胞白血病中的药代动力学。
Expert Opin Drug Metab Toxicol. 2021 Sep;17(9):1023-1030. doi: 10.1080/17425255.2021.1955855. Epub 2021 Jul 28.
4
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.阿卡替尼及其在慢性淋巴细胞白血病治疗中的应用。
Future Oncol. 2022 Mar;18(7):755-769. doi: 10.2217/fon-2021-0602. Epub 2022 Feb 10.
5
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).布鲁顿酪氨酸激酶抑制剂：用于慢性淋巴细胞白血病（CLL）患者的第一代和第二代药物。
Expert Opin Investig Drugs. 2018 Jan;27(1):31-42. doi: 10.1080/13543784.2018.1404027. Epub 2017 Nov 15.
6
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.伊布替尼联合治疗 CLL：科学依据和临床结果。
Blood Cancer J. 2021 Apr 29;11(4):79. doi: 10.1038/s41408-021-00467-7.
7
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.慢性淋巴细胞白血病的诊断与治疗：综述
JAMA. 2023 Mar 21;329(11):918-932. doi: 10.1001/jama.2023.1946.
8
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
9
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.阿卡拉布替尼联合奥滨尤妥珠单抗治疗初治及复发/难治性慢性淋巴细胞白血病
Cancer Discov. 2020 Mar;10(3):394-405. doi: 10.1158/2159-8290.CD-19-1130. Epub 2020 Jan 8.
10
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.依鲁替尼治疗后进展的慢性淋巴细胞白血病的维奈托克：多中心、开放标签、2 期试验的中期分析。
Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.
引用本文的文献
1
Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents.慢性淋巴细胞白血病：靶向药物时代不良事件的管理
Cancers (Basel). 2024 May 24;16(11):1996. doi: 10.3390/cancers16111996.
2
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.布鲁顿酪氨酸激酶抑制剂治疗B细胞恶性肿瘤中国专家共识
Exp Hematol Oncol. 2023 Oct 16;12(1):92. doi: 10.1186/s40164-023-00448-5.
3
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.临床实践中监测和管理布鲁顿酪氨酸激酶（BTK）抑制剂治疗相关不良事件
Front Oncol. 2021 Nov 8;11:720704. doi: 10.3389/fonc.2021.720704. eCollection 2021.
本文引用的文献
1
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.ASCEND：阿卡替尼对比伊布替尼联合利妥昔单抗或苯达莫司汀联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病的 III 期随机试验。
J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27.
2
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.阿卡替尼联合或不联合奥滨尤妥珠单抗对比苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（ELEVATE TN）：一项随机、对照、III 期临床试验。
Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.
3
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.布鲁顿酪氨酸激酶抑制剂治疗复发或难治性套细胞淋巴瘤的研究进展。
Curr Oncol. 2019 Apr;26(2):e233-e240. doi: 10.3747/co.26.4345. Epub 2019 Apr 1.
4
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.随机对照试验：伊布替尼对比伊布替尼联合利妥昔单抗治疗慢性淋巴细胞白血病患者。
Blood. 2019 Mar 7;133(10):1011-1019. doi: 10.1182/blood-2018-10-879429. Epub 2018 Dec 7.
5
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.
6
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.伊布替尼方案与化疗免疫治疗在未经治疗的老年 CLL 患者中的比较。
N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.
7
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.阿卡拉布替尼（ACP-196）：一种具有独特选择性和体内药效学特征的共价布鲁顿酪氨酸激酶抑制剂。
J Pharmacol Exp Ther. 2017 Nov;363(2):240-252. doi: 10.1124/jpet.117.242909. Epub 2017 Sep 7.
8
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.选择性布鲁顿酪氨酸激酶抑制剂阿卡拉布替尼与依鲁替尼在慢性淋巴细胞白血病细胞中的比较。
Clin Cancer Res. 2017 Jul 15;23(14):3734-3743. doi: 10.1158/1078-0432.CCR-16-1446. Epub 2016 Dec 29.
9
Second-generation inhibitors of Bruton tyrosine kinase.布鲁顿酪氨酸激酶第二代抑制剂
J Hematol Oncol. 2016 Sep 2;9(1):80. doi: 10.1186/s13045-016-0313-y.
10
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.依鲁替尼对比替西罗莫司治疗复发或难治性套细胞淋巴瘤患者：一项国际性、随机、开放标签、3 期研究。
Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7.
Zotero 插件